Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422981 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
A Phase 2 study of Mild Cognitive Impairment, So Stated, sponsored by Allon Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 17
- Study locations
NCT00422981 is a Phase 2 study of Mild Cognitive Impairment, So Stated that has completed, run by Allon Therapeutics. The registered enrollment target is 144 participants. The trial reports 17 study locations across 10 states.
The verdict
NCT00422981, a Phase 2 study of Mild Cognitive Impairment, So Stated, has completed, sponsored by Allon Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AL-108
Study Locations (17)
Florida
- Meridien Research - Brooksville
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Clinical Neuroscience Solutions - Orlando
- Meridien Research - Tampa
- Stedman Clinical Trials - Tampa
- Clinical Research Center of Indian River Medical Center - Vero Beach
California
- Collaborative Neuroscience Network - Garden Grove
- Synergy Research - National City
- Pacific Research Network, Inc - San Diego
Arizona
- Pivotal Research - Peoria
Illinois
- Comprehensive Neuroscience - Hoffman Estates
New Jersey
- The Memory Enhancement Center of America - Long Branch
New York
- SPRI Clinical trials - Brooklyn
North Carolina
- Memory Assessment and Research Services - Wilmington
Ohio
- Neurology & Neuroscience Center of Ohio - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422981
The ClinicalTrials.gov registry entry for NCT00422981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allon Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Cognitive Impairment, So Stated appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00422981 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00422981 about?
NCT00422981 is a clinical study titled "Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment". The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
What is the current status of trial NCT00422981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2007-01. Estimated completion is 2008-01.
What conditions does trial NCT00422981 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, So Stated.
What interventions are being tested in trial NCT00422981?
The interventions under investigation include: Placebo (DRUG), AL-108 (DRUG).
Who is sponsoring clinical trial NCT00422981?
This trial is sponsored by Allon Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00422981 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.